CD38 and Miyoshi myopathy: Furthermore, the cellular therapy with KHYG1, CD38KO NK cells or g-NK cells protects the immune activity of NK cells by upregulating the quantity or activity of CD38low/- NK cells and preventing the HLA-E-mediated immune evasion to maximize the effects of CD38 mAb against MM.